Posted on May 31st, 2010 by
Bristol-Myers Squibb’s (NYSE:BMY) cancer drug ipilimumab is expected to demonstrate durable responses in a limited subset of patients with second-line melanoma, a number of oncologists told Pharmawire. The agent will also be effective as a monotherapy, some noted.
Tags: In the News
You must be logged-in to the site to post a comment.